Navigation Links
IsoPlexis Collaboration Offers Breakthrough Insights into Detecting and Predicting Patient Response to T-Cell Therapy
Date:4/3/2017

WASHINGTON, April 3, 2017 /PRNewswire-USNewswire/ -- Data captured by IsoCode, IsoPlexis Corporation's (IsoPlexis) single-cell precision engineering platform, detected a statistically significant association between the potency of CAR-T cell product prior to treatment and objective response of cancer patients post-treatment. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy prior to treatment, as well as to improve both pre-infusion potency testing and cell product design.

These findings, the result of a collaboration between IsoPlexis and Kite, were presented today at the American Association for Cancer Research's Annual Meeting. 

"IsoPlexis was excited to collaborate with Kite on this groundbreaking research," said IsoPlexis Chief Executive Officer Sean Mackay. "Using our single-cell precision engineering platform, leading oncology and immunotherapy researchers and clinicians were able to collect these data, which demonstrate a potential to optimize therapies and therapeutic interventions for patients, and ultimately drive better patient outcomes in this rapidly growing field."

Researchers used IsoCode, previously referred to as SCBC in the literature, to analyze CAR-T cell therapy products for 20 patients with non-Hodgkin lymphoma. Using IsoCode, researchers captured data to determine the PSI, or cellular functional profile and strength, of each product. This PSI metric was able to predict complete or partial patient response to the product, with statistical significance.

Adrian Bot, M.D., Kite's Vice President, Translational Medicine, said, "Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer, leading to new ways to characterize and optimize T-cell products. These insights were made possible by using the IsoPlexis technology."

Arnold Levine, PhD, Professor Emeritus of Systems Biology at the Institute for Advanced Study in Princeton and an IsoPlexis Scientific Advisory Board Member, said, "The quality and precision of these data captured by IsoPlexis technology is exceptional and permits for the first time real precision medicine and early intervention in T-cell production." He added, "IsoPlexis technology can help researchers improve the development and targeting of treatments, enabling truly precise medicine and better patient outcomes."

The abstract is available online: http://www.abstractsonline.com/pp8/#!/4292/presentation/1309

A webcast of the presentation will be posted on the AACR website on April 26.

ABOUT ISOPLEXIS:

IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Caltech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut. For additional information on IsoPlexis, visit http://www.isoplexis.com or email info@isoplexis.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isoplexis-collaboration-offers-breakthrough-insights-into-detecting-and-predicting-patient-response-to-t-cell-therapy-300432888.html


'/>"/>
SOURCE IsoPlexis Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Personalized Medicine - Scientific and Commercial Aspects - 318 Companies Profiled with 575 Collaborations - Research and Markets
2. STMicroelectronics and Valencell Announce Collaboration on Highly Accurate and Powerful Biometric Sensor Platform for Wearables and IoT
3. FIND And Cepheid Announce A Strategic Collaboration To Advance Point-Of-Care TB Diagnosis
4. NXT-ID, Inc. Announces Collaboration with Celebrity Joey Fatone
5. Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health
6. Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc
7. Collaboration drives achievement in protein structure research
8. Calico enters into exclusive collaboration with 2M to develop UTSW technology
9. Research institutions announce collaboration for sharing, standardizing neuroscience data
10. Urban Water Management Workshop stresses more collaboration and innovation
11. ASHG and the Jackson Laboratory launch educational collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2018)... ... August 16, 2018 , ... ... first private cord blood bank to separate and store stem cells in 1992, ... and Brian Sheehy, M.D. M.A. C.F.A., Founder and Managing Partner IsZo Capital, have ...
(Date:8/15/2018)... ... August 15, 2018 , ... The Florida Chiropractic ... FX 635 Laser’s unveiling. Doctors from around the U.S. will gain firsthand insights ... 635, Erchonia Corporation completed another successful clinical trial that has resulted in ...
(Date:8/14/2018)... ... 13, 2018 , ... Quantification in body fluids like plasma/serum ... the body as well as capturing drugs and their metabolites, in addition lifestyle-based ... , By performing Nuclear Magnetic Resonance (MNR) on body fluid samples, the role ...
Breaking Biology News(10 mins):
(Date:7/24/2018)... ... July 24, 2018 , ... Boval was founded in 1978 when ... suppliers. In Boval’s early days most of the BSA manufactured was for blood ... for diagnostic purposes after gel cards changed that market and displaced most of the ...
(Date:7/22/2018)... ... July 19, 2018 , ... CallTower ... their team. With more than ten years of strategic, result-oriented Channel experience and ... as CallTower’s Channel Director for the Southwest and Mountain region. , As an ...
(Date:7/22/2018)... ... July 19, 2018 , ... The Center for ... generously supported by the Laura and John Arnold Foundation and MedImmune. The overarching ... and developed at 55 institutions, including the National Institutes of Health, the United ...
(Date:7/22/2018)... ... July 21, 2018 , ... Today the Weed Science Society of ... movement of dicamba herbicides is available on the Society’s website . The workshop ... stakeholders better understand and manage factors contributing to dicamba off-target movement. , ...
Breaking Biology Technology: